Crossmark

Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden

Published Online: 2024-09-10

Published Print: 2024-12

Authors

Sasaki, Akinori

Nakajima, Satoru

Motomura, Yasuaki
License Information

Text and Data Mining valid from 2024-09-10

Version of Record valid from 2024-09-10
More Information

Article History

Accepted: 2 September 2024

First Online: 10 September 2024

Declarations

:

: Consent for publication of the case was provided by the patient.

: The authors declare no competing interests.

Document is current